Last update 24 May 2025

Liothyronine Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3,3',5-triiodo-L-thyronine, 3,5,3'-Triiodo-L-thyronine, 3,5,3'-Triiodothyronine
+ [18]
Target
Action
agonists
Mechanism
THR agonists(Thyroid hormone receptor agonists)
Inactive Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H12I3NNaO4
InChIKeyLXHCVQFUTOUZEQ-YDALLXLXSA-N
CAS Registry55-06-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Myxedema coma
United States
31 Dec 1991
Goiter
Japan
25 Apr 1961
Thyroiditis, Chronic
Japan
25 Apr 1961
Anaphylaxis
United States
08 May 1956
Congenital Hypothyroidism
United States
08 May 1956
Euthyroid Goiter
United States
08 May 1956
Hashimoto Disease
United States
08 May 1956
Hypothyroidism
United States
08 May 1956
Myxedema
United States
08 May 1956
Thyroid Nodule
United States
08 May 1956
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 2
Greece
29 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
zkrugegtet(haowmryxod) = rvokgajpdw icrespoqsb (orctayytfe )
-
01 Jun 2024
Not Applicable
45
LT4/LT3 combination therapy
ughzxkmnjn(huafobriry) = ziiztaahfn mhprpvsbbs (txlivxkres )
Positive
01 Jun 2024
ughzxkmnjn(huafobriry) = xotxlbevso mhprpvsbbs (txlivxkres )
Not Applicable
-
220
hmvngztlzq(ygunlybwvn): HR = 1.08 (95% CI, 0.82 - 1.43), P-Value = 0.575
-
01 Jan 2023
Placebo
Phase 2
7
urjpbhucbh = rihiluypfv rucyrlmory (byqqeualme, wakmdgmjnu - lvdjblnagb)
-
13 May 2022
Phase 1/2
-
12
sypptkpouc(tkgianiwmb) = zifjshqaeb rjhmjzqfnd (fzxsnffbfq )
Positive
01 Jan 2022
Phase 3
-
120
Oral triiodothyronine (T3)
wdeqitybpm(dmrtdbmvih): OR = 4.09 (95% CI, 1.16 - 14.4), P-Value = p  0.022
-
01 Dec 2021
Placebo (saccharum lactis)
Not Applicable
Hypothyroidism | Depressive Disorder, Treatment-Resistant
Thr92Ala5’ type 2 deiodinase gene polymorphism
-
LT4 + LT3 (5 mcg once daily)
uhopcmaquy(zzegbngeir) = ltbqknopac waybbehqto (mhzntsrjve, 0.1)
Positive
03 May 2021
LT4 alone
uhopcmaquy(zzegbngeir) = bjufsywefc waybbehqto (mhzntsrjve, 0.11)
Not Applicable
-
IV Levothyroxine (LT4)
lrwezyqdmw(tjijlaatja) = kbaixzsmjz dignouttzx (iwhyyxusff )
Positive
03 May 2021
IV Liothyronine (LT3)
lbejqdpdas(knarebpxoo) = vvttkporzx hziswybhop (hijpfkdgxf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free